ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic lupus erythematosus (SLE)"

  • Abstract Number: 2674 • 2014 ACR/ARHP Annual Meeting

    The Effect and Mechanisms of Icaritin on Regulating Foxp3/IL17a Expression in CD4+  T Cells from SLE

    Jieyue Liao1, Yu Liu2, Ming Zhao3, hai Jing Wu4 and Qianjin Lu5, 1Department of Dermatology, Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China, 2Department of Dermatology, Second Xiangya Hospital, Central South University, shangcha, China, 3Department of Dermatology, Second Xiangya Hospital, Central South University, changsha, China, 4Department of Dermatology, Second Xiangya Hospital, Central South University, sahngsha, China, 5Department of Dermatology, Second Xiangya Hospital, Central South University, Changsha, China

    Background/Purpose : Systemic lupus erythematosus (SLE) is a female predominant autoimmune disease characterized by overproduction of autoantibodies. The pathogenesis of SLE is complex. Several studies…
  • Abstract Number: 2689 • 2014 ACR/ARHP Annual Meeting

    The CUL4CRBN E3 Ubiquitin Ligase Modulator CC-220 Induces Degradation of the Transcription Factors Ikaros and Aiolos: Immunomodulation in Healthy Volunteers and Relevance to Systemic Lupus Erythematosus

    Peter H. Schafer1, Ying Ye2, Lei Wu3, Jolanta Kosek4, Zhihong Yang5, Liangang Liu5, Michael Thomas5, Maria Palmisano5 and Rajesh Chopra5, 1Celgene Corporation, Celgene Corporation, Summit, NJ, 286 Morris Avenue, Celgene Corporation, Summit, NJ, 3Department of Translational Development, Celgene Corporation, Summit, NJ, 4Translational Development, Celgene Corporation, Summit, NJ, 5Celgene Corporation, Summit, NJ

    Background/Purpose: CC-220 is an immunomodulatory compound that binds to cereblon (CRBN), part of the CUL4CRBN E3 ubiquitin ligase complex, which has been shown to ubiquitinate…
  • Abstract Number: 2667 • 2014 ACR/ARHP Annual Meeting

    First-Trimester Disease Activity Does Not Predict Pre-Eclampsia in SLE Pregnancy

    Khaled Alderaan1, Laurence S. Magder2 and Michelle Petri3, 1King Fahad Specilaist Hospital, Dammam, Saudi Arabia, 2Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Preeclampsia complicates up to 35% of lupus pregnancies compared to 8% of general population pregnancies. SLE has up to a 3-fold increased rate of…
  • Abstract Number: 2635 • 2014 ACR/ARHP Annual Meeting

    Noncalcified Plaque Progression in Systemic Lupus Erythematosus

    Adnan Kiani1, Armin Zadeh2, Joao Lima2, Laurence S. Magder3 and Michelle Petri4, 11830 E Monument St, Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 4Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose:   Coronary atherosclerosis is a major cause of morbidity and mortality in SLE.  New technology, computed tomoangiography (CTA) can measure non-calcified coronary plaque (NCP),…
  • Abstract Number: 2648 • 2014 ACR/ARHP Annual Meeting

    Prednisone Is a Risk Factor for Incident Depression in Systemic Lupus Erythematosus

    Xiangyang Huang1, Laurence S. Magder2 and Michelle Petri3, 1Sichuan University School of Medicine, Sichuan, China, 2Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Depression affects as many as 30% of SLE patients.  Most studies of risk factors for depression among SLE patients have been cross-sectional, and thus…
  • Abstract Number: 2647 • 2014 ACR/ARHP Annual Meeting

    Predictors of Incident Seizure in Systemic Lupus Erythematosus

    Xiangyang Huang1, Laurence S. Magder2 and Michelle Petri3, 1Sichuan University School of Medicine, Sichuan, China, 2Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: We identified the rate and risk factors for first occurrences of seizure based on a large closely followed longitudinal cohort of patients with systemic…
  • Abstract Number: 2622 • 2014 ACR/ARHP Annual Meeting

    Systemic LUPUS Erythematosus in Spanish Males

    Anne Riveros-Frutos1, Irma Casas2, Iñigo Rúa-Figueroa3, José Maria Pego-Reigosa4, M. Jesús García de Yebenes5, Alejandro Olivé6, Jose Rosas7, Paloma Vela8, Monica Ibanez Barcelo9, Vicente Torrente10, Ivan Castellvi11, Javier Narváez12, Mireia Moreno13, R. Blanco Alonso14, Víctor Martínez Taboada15, Jaime Calvo-Alen16, Mª Angeles Aguirre17, Mercedes Freire18, Enrique Raya19, Celia Erausquin20, Esther Uriarte21, Elvira Díez Álvarez22, Tomás Vázquez Rodríguez23, Antonio Fernández Nebro24, Eva Tomero25, Paloma García de la Peña26, Ana Sánchez Atrio27, Monica Fernández de Castro28, Antonio Zea29, Patricia Richi30, Francisco Lopez Longo31, María Galindo-Izquierdo32, Patricia Carreira33, Gema Bonilla34, Carlos Marras Fernández Cid35, Maria Loreto Horcada36, Carlos Montilla37, Blanca Hernández-Cruz38, José Marenco de la Fuente39, Marian Gantes40, Olaia Fernández Berrizbeitia41, Juan J. Alegre42, Ángela Pecondón Español43, Manuel Rodríguez-Gómez44, Victor Quevedo45, José Hernández Beiraín46 and Lucía Silva Fernández47, 1Rheumatology, Hospital Universitario Germans Trias i Pujol, Badalona, Spain, 2Preventive Medicine, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 3Rheumatology, Hospital Doctor Negrin, Las Palmas de Gran Canaria, Spain, 4Rheumatology, Hospital Meixoeiro, Vigo, Spain, 5Rheumatology, Research Unit of the SER, Madrid, Spain, 6Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 7Rheumatology, Hospital Marina Baixa. Villajoyosa, Villajoyosa, Spain, 8Rheumatology, Hospital General de Alicante. Spain, Alicante, Spain, 9H. Son Llatzer, Palma de Mallorca, Spain, 10Rheumatology, Hospital Moisès Broggi, Barcelona, Spain, 11Unitat de Reumatologia., Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 12Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, 13Rheumatology, Hospital Parc Taulí, Sabadell, Spain, 14Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, 15Rheumatology, Marqués de Valdecilla, Santander, Spain, 16Rheumatology, Hospital de Sierrallana. Torrelavega. Spain, Torrelavega, Spain, 17Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, 18Rheumatology, Hospital Universitario Juan Canalejo, La Coruña, Spain, 19Rheumatology, University Hospital San Cecilio, Granada, Spain, 20Rheumatology, Hospital Dr, Negrín, Las Palmas Gran Canarias, Spain, 21Rheumatology, Hospital de Donosti, San Sebastian, Spain, 22Rheumatology, Hospital de León. Spain, León, Spain, 23Rheumatology, Hospital Lucus Augusti, Lugo, Spain, 24Rheumatology, Hospital Carlos Haya. Malaga, Malaga, Spain, 25Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 26Rheumatology, Hospital Norte Sanchinarro, Madrid, Spain, 27Hospital Príncipe de Asturias, Immune System Diseases/Rheumatology department, Alcalá de Henares, Madrid, Spain, 28Hospital Puerta del Hierro, Madrid, Spain, 29Rheumatology, Hospital Universitario Ramon y Cajal, Madrid, Spain, 30Hospital Infanta Sofía, Madrid, Spain, 31Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, 32Rheumatology, Hospital 12 de octubre, Madrid, Spain, 33Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, 34Rheumatology, Hospital La Paz, Madrid, Spain, 35Hospital Virgen de la Arrixaca, Murcia, Spain, 36Rheumatology, Complejo Hospitalario de Navarra, Pamplona, Spain, 37Rheumatology, Hospital Clínico Universitario de Salamanca, Salamanca, Spain, 38Rheumatology, University Hospital Virgen Macarena, Sevilla, Spain, 39Rheumatology, Hospital de Valme, Sevilla, Spain, 40Rheumatology, Hospital Universitario de Canarias, Tenerife, Spain, 41Rheumatology, Hospital de Basurto, Bilbao, Spain, 42Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, 43Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, 44Rheumatology, Complejo Hospitalario Universitario de Ourense, Ourense, Spain, 45Rheumatology, Hospital de Monforte, Lugo, Spain, 46Rheumatology, Hospital Insular de Gran Canaria, Las palmas Gran Canarias, Spain, 47Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain

    Background/Purpose: To describe the demographic, clinical and immunological manifestations in male patients with Systemic Lupus Erythematosus(SLE) Methods: Patients diagnosed of SLE that were in the…
  • Abstract Number: 1859 • 2014 ACR/ARHP Annual Meeting

    Age-Specific Predictors of Mortality in SLE

    Dominique Ibanez1, Dafna D. Gladman2 and Murray B. Urowitz2, 1Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Mortality is 3 to 5 times greater in SLE patients then it is in the general population – especially among younger patients where it…
  • Abstract Number: 1652 • 2014 ACR/ARHP Annual Meeting

    Biomarkers of Lupus Nephritis and Ethnic Disparities in Systemic Lupus Erythematosus

    Adnan Kiani1, Laurence S. Magder2 and Michelle Petri3, 11830 E Monument St, Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Lupus nephritis eventually occurs in 50% of Caucasian SLE patients and 75% of African-Americans.  African Americans have a more severe presentation of SLE and…
  • Abstract Number: 1595 • 2013 ACR/ARHP Annual Meeting

    Electroclinical Correlates and Outcome Of Status Epilepticus In Systemic Lupus Erythematosus

    Jamal Mikdashi1, Tricia Ting2 and Allan Krumholz3, 1Division of Rheumatology and Clinical Immunology, University of Maryland School of Medicine, Baltimore, MD, 2Neurology, University of Maryland. School of Medicine, Baltimore, MD, 3Neurology, University fo Maryland school of Medicine, Baltimore, MD

    Background/Purpose: Predictors of seizures and epilepsy in systemic lupus erythematosus (SLE) patients are well described but descriptions of status epilepticus (SE) have thus far been…
  • Abstract Number: 1577 • 2013 ACR/ARHP Annual Meeting

    Comparison Of Clinical and Serological Manifestations Among Juvenile-, Adult-, and Late-Onset Systemic Lupus Erythematosus Patients In Korea

    Dong-Jin Park1, Ji-Hyoun Kang2, Kyung-Eun Lee1, Jeong-Won Lee2, Lihui Wen1, Tae-Jong Kim3, Yong-Wook Park1 and Shin-Seok Lee4, 1Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, 2Chonnam National University Medical School, Gwangju, South Korea, 3Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea, 4Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea

    Background/Purpose: Up to 30‑40% of patients with systemic lupus erythematosus (SLE) experience their onset prior to adulthood or at over 50 years of age. Patients…
  • Abstract Number: 1060 • 2013 ACR/ARHP Annual Meeting

    Perinatal Risk Factors For Systemic Lupus: A Register-Based Case-Control Study

    Elizabeth V. Arkema1 and Julia F. Simard2,3, 1Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Depts of Health Research and Policy and Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA, 3Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: One’s own fetal environment has been linked to future heart disease, breast cancer, and rheumatoid arthritis. Prior work showed that among older women in…
  • Abstract Number: 586 • 2013 ACR/ARHP Annual Meeting

    Blood Pressure Variability and Age-Related Blood Pressure Patterns In Systemic Lupus Erythematosus

    George Stojan1, Laurence S. Magder2 and Michelle Petri3, 1Div of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 2Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, 3Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Increased visit-to-visit blood pressure (BP) variability has been associated with an increased risk of all-cause mortality, stroke, left ventricular diastolic dysfunction, and cognitive impairment…
  • Abstract Number: 597 • 2013 ACR/ARHP Annual Meeting

    Low Complement (C3), Male Gender and Methotrexate Use Are Associated With Noncalcified Plaque In Systemic Lupus Erythematosus

    Adnan Kiani1, Armin Zadeh2, Jens Vogel-Claussen1, Joao Lima2, Laurence S. Magder3 and Michelle Petri1, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Johns Hopkins University, Baltimore, MD, 3Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD

    Background/Purpose: New technology (CTA) can measure non-calcified coronary plaque (NCP), which is highly unstable and prone to rupture.  We quantified NCP in SLE and determined…
  • Abstract Number: 574 • 2013 ACR/ARHP Annual Meeting

    Oral Candidiasis in Systemic Lupus Erythematosus

    Monthida Fangtham, Hong Fang and Michelle Petri, Johns Hopkins University School of Medicine, Baltimore, MD

    Background/Purpose: Candida is the most common opportunistic fungal infection identified in SLE. In a previous autopsy study, 14 percent of deaths in SLE patients were…
  • « Previous Page
  • 1
  • …
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology